The aim of this systematic review and meta‐analysis was to assess the risk of acute pancreatitis and pancreatic cancer among patients taking glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). Here, GLP1R is linked to acute pancreatitis.